Interleukin-3 data

A Phase I/II trial of IL-3 and GM-CSF in patients with Hodgkin's disease and in non-Hodgkin's lymphoma undergoing autologous bone marrow transplant (ABMT) showed that sequential administration was safe and may spur faster recovery of neutrophils and platelets than GM-CSF alone. Median time to a neutrophil count above 500 was 15 days, whereas a historical control is 19 days with GM-CSF alone. Platelet recovery time was a median of 16 days to achieve a count of 20,000, with the historical control being 26 days with GM-CSF alone, the company said.

Sequential treatment consisted of daily IL-3 for five or 10 days and then daily G-CSF until neutrophil counts recovered; simultaneous treatment involved daily administration of both cytokines until neutrophil recovery. Phase II and III trials of the sequential therapy are underway. ...